Calls for papers
-
HCmed Innovations announced that the FDA has granted 510(k) clearance to the company’s AdheResp connected breath-actuated mesh nebulizer, which delivers aerosol during inhalation only. According to the company, AdheResp is the first nebulizer of its… Read more . . .
-
According to ARS Pharmaceuticals, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the company’s marketing application for EURneffy adrenaline nasal spray for the emergency treatment of anaphylaxis in patients who weigh more than 30… Read more . . .
-
BiomX announced that it has initiated a Phase 2b study of its BX004 inhaled phage cocktail cystic fibrosis patients with chronic P. aeruginosa lung infections. BiomX had said in November 2023 that it planned to advance… Read more . . .
-
Oragenics, which recently announced that it had raised approximately $16.5 million for Phase 2 development of its OPN-002 neurosteroid nasal powder for the treatment of mild traumatic brain injury, says that Sterling Pharma Services will… Read more . . .
-
Aptar Pharma announced that it has acquired OINDP specialist CDMO Mod3 Pharma (formerly Enteris Biopharma). According to Mod3’s web site, Enteris was created in 2013 with assets and personnel from Unigene, which manufactured Fortical calcitonin… Read more . . .
-
Hong Kong-based Guangdong Hengrui Pharmaceuticals’s parent company Jiangsu Hengrui Pharmaceuticals announced that Guangdong Hengrui has received approval from the Chinese National Medical Products Administration (NMPA) for a clinical trial of its HRS-9821 DPI, which the… Read more . . .
-
Merck has announced that it will acquire Ohtuvarye inhaled ensifentrine maker Verona Pharma for a total of approximately $10 billion. Ohtuvarye, which is delivered via jet nebulizer, was approved by the FDA in June 2024… Read more . . .
-
Evoke Pharma announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a continuation of US Patent No. 11,517,545 (“Treatment of Moderate and Severe Gastroparesis”), which was issued… Read more . . .
-
Oragenics announced that it has raised approximately $16.5 million in a Series H funding round, with proceeds going toward repayment of a $3 million bridge loan and continued development of the company’s OPN-002 neurosteroid nasal… Read more . . .
-
German startup Ebenbuild has received a €2.3 million grant plus a commitment for up to an additional €10 million in future investments from the European Innovation Council (EIC) Accelerator program, the company said. The funding… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA